Federal contract award
75F40122C00148
TO CHARACTERIZE THE CLINICAL PRESENTATION OF C-VAM/TO CONTRAST C-VAM WITH CARDIAC COMPLICATIONS OF INFECTION WITH SARS-COV-2 THAT THE IMMUNIZATION SEEKS TO PREVENT/TO INFORM BEST PRACTICES FOR SURVEILLANCE AND MONITORING FOR C-VAM, INCLUDING IN ASYMP
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $2.6M |
| Current contract value | $2.6M |
| Potential contract value / ceiling | $2.6M |
| Start date | Sep 26, 2022 |
| Current end date | Sep 27, 2027 |
| Potential end date | Sep 27, 2027 |
| Latest award activity | Sep 22, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 3 of 3 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 22, 2025 | P00002 | $576.5K | TO CHARACTERIZE THE CLINICAL PRESENTATION OF C-VAM/TO CONTRAST C-VAM WITH CARDIAC COMPLICATIONS OF INFECTION WITH SARS-COV-2 THAT THE IMMUNIZATION SEEKS TO PREVENT/TO INFORM BEST PRACTICES FOR SURVEILLANCE AND MONITORING FOR C-VAM, INCLUDING IN ASYMP |
| Aug 12, 2025 | P00001 | $0 | TO CHARACTERIZE THE CLINICAL PRESENTATION OF C-VAM/TO CONTRAST C-VAM WITH CARDIAC COMPLICATIONS OF INFECTION WITH SARS-COV-2 THAT THE IMMUNIZATION SEEKS TO PREVENT/TO INFORM BEST PRACTICES FOR SURVEILLANCE AND MONITORING FOR C-VAM, INCLUDING IN ASYMP |
| Sep 26, 2022 | 0 | $2.0M | TO CHARACTERIZE THE CLINICAL PRESENTATION OF C-VAM/TO CONTRAST C-VAM WITH CARDIAC COMPLICATIONS OF INFECTION WITH SARS-COV-2 THAT THE IMMUNIZATION SEEKS TO PREVENT/TO INFORM BEST PRACTICES FOR SURVEILLANCE AND MONITORING FOR C-VAM, INCLUDING IN ASYMP |
Estimated positioning window
Nov 1, 2026 – Mar 27, 2027
60/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 60/100. Available recorded signals: 55 points.
- Contract end 2027-09-27 (330 days from calculation)
- +35 points
- 46 historical awards in this buyer and category group
- +15 points
- 3 recorded award transactions
- +5 points
- Latest award action: 2025-09-22
- +0 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +0 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.